uploads///Vaccine

Behind Merck’s Vaccines Gardasil, Pneumovax 23, and ProQuad: A Post-4Q17 Performance Update

By

Mar. 16 2018, Updated 10:30 a.m. ET

Gardasil-Gardasil 9 revenue trends

In 4Q17, Merck’s (MRK) Gardasil-Gardasil 9 generated revenues of $633 million, which reflected a ~17% rise on a YoY (year-over-year) basis and a 6% fall on a QoQ (quarter-over-quarter) basis.

In 4Q17, in the US and in international markets, Gardasil-Gardasil 9 reported revenues of $370 million and $262 million, respectively, compared with $409 million and $134 million in 4Q16. In fiscal 2017, Merck’s Gardasil-Gardasil 9 generated revenues of $2.31 billion, compared with $2.17 billion in 2016, which reflected a ~6% YoY rise.

In 2017, in the US and in international markets, Gardasil-Gardasil 9 generated revenues of $1.57 billion and $743 million, respectively, compared with $1.78 billion and $393 million in 2016, which reflected a ~12% decline and an 89% rise on a YoY basis.

In the marketplace, Gardasil’s peers in the anti-human papillomavirus infection vaccine market include GlaxoSmithKline’s Cervarix.

Article continues below advertisement

ProQuad-MMR=II-Varivax revenue trends

In 4Q17, Merck’s ProQuad-MMR=II-Varivax reported revenues of $103 million, compared with $405 million in 4Q16. In 4Q17, in the US and in international markets, ProQuad-MMR=II-Varivax generated revenues of $316 million and $88 million, respectively, compared with $308 million and $97 million in 4Q16, which reflected a ~2% YoY rise and a ~9% QoQ fall.

In fiscal 2017, ProQuad-MMR=II-Varivax reported revenues of $1.68 billion, compared with $2.17 billion in 2016. In 2017, in the US and in international markets, ProQuad-MMR-II-Varivax generated revenues of $1.37 billion and $303 million, respectively, compared with $1.36 billion and $279 million in 2016, which was ~1% higher and 9% higher, respectively, YoY.

Pneumovax 23 revenue trends

In 4Q17, Pneumovax 23 generated revenues of $263 million, compared with $238 million in 4Q16, which reflected a ~11% YoY rise and a 15% QoQ (quarter-over-quarter) rise.

In 4Q17, in the US and in international markets, Pneumovax reported revenues of $189 million and $74 million, respectively, which reflected a ~5% rise and a ~28% rise YoY.

In fiscal 2017, Merck’s Pneumovax 23 reported revenues of $821 million, compared with $641 million in 2016, which reflected ~28% growth on a YoY basis. In 2017, in the US and in international markets, Pneumovax 23 reported revenues of $581 million and $240 million, respectively, compared with $447 million and $193 million in 2016, which was ~30% higher and 24% higher, respectively, on a YoY basis.

Notably, in 2017, vaccines market peers GlaxoSmithKline (GSK), Sanofi (SNY), and Pfizer (PFE) reported revenues of $38.9 billion, $39.5 billion, and $52.5 billion, respectively.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.